Overview

Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this research is to study the efficacy and safety of AMG 073 in patients with kidney failure who are being treated with hemodialysis or peritoneal dialysis and who also have secondary hyperparathyroidism (HPT).
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Cinacalcet
Cinacalcet Hydrochloride